Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia
Approximately 20% of patients with acute myeloid leukaemia (AML) have a mutation in FMS-like-tyrosine-kinase-3 (FLT3). FLT3 is a trans-membrane receptor with a tyrosine kinase domain which, when activated, initiates a cascade of phosphorylated proteins including the SRC family of kinases. Recently o...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Nature Publishing Group
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544001/ |